Depression market value to drop as pharma battles second cliff
This article was originally published in Scrip
As the second patent cliff for top-selling depression drugs approaches, the value of the depression market is set to decline from $5.6bn in 2012 to $4.7bn in 2016 in the seven major markets, new analysis indicates.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.